

Reacta Healthcare transforms into facility for multi-allergen manufacturing

13 June 2025 | News

All development and manufacturing of the new products have been conducted at Reacta Healthcare's Medicines and Healthcare products Regulatory Agency (MHRA) licensed facility in Deeside, UK



All development and manufacturing of the new products have been conducted at Reacta Healthcare's Medicines and Healthcare products Regulatory Agency (MHRA) licensed facility in Deeside, UK

In May 2025, Reacta Healthcare achieved a significant milestone with the launch of its first production run of pharmaceutical-grade milk and egg challenge meals. These initial orders will be shipped internationally to support two clinical trials focused on innovative treatments for food allergies.

The need to consider multiple food allergies in both diagnosis and treatment has become increasingly important. Among individuals with food allergies, 46 per cent of adults and 40 per cent of children have multiple allergies. This underscores the necessity for healthcare providers to adopt a holistic approach in management.

The introduction of egg and milk challenge meals, alongside the existing peanut products, highlights the prevalence of multiple food allergies. These meals are specifically designed to meet the needs of food allergy research and clinical communities, ensuring safety, quality, and efficacy across various allergens. The development of these new standardised allergen products enables the easy expansion of Reacta Healthcare's product portfolio to include additional allergens.

All development and manufacturing of the new products have been conducted at Reacta Healthcare's Medicines and Healthcare products Regulatory Agency (MHRA) licensed facility in Deeside, UK. The challenge meals adhere to client requirements for allergen identification, standardisation, and current Good Manufacturing Practices (cGMP). Since 2017, successful submissions of dossiers for these products have been made to various health agencies, including the FDA and EMA.